Ligand is a biopharmaceutical royalty company that earns revenue by owning royalty interests on drugs developed and commercialized by partners, rather than developing drugs itself. Ligand invests capital upfront in exchange for contractual rights to receive a percentage of future drug sales, then collects royalties as those drugs generate revenue. The company's portfolio spans over 100 commercial and development-stage programs, with 12 major commercial royalty assets driving the bulk of royalty revenue. Key assets include Kyprolis (multiple myeloma, Amgen), Qarziba (neuroblastoma, Recordati), Filspari (IgA nephropathy, Travere), and Ohtuvayre (COPD, Merck). Ligand deploys capital through four main approaches: purchasing existing royalty rights, providing development capital for late-stage clinical programs in exchange for synthetic royalties, acquiring distressed assets with embedded royalty potential, and owning royalty-generating technology platforms. Beyond financial royalties, Ligand owns two proprietary technology platforms: Captisol, a patented excipient that improves drug solubility and is a key ingredient in 17 FDA-approved drugs, and NITRICIL, a nitric oxide-based platform for topical therapies. Ligand generates revenue through royalties, Captisol material sales, and contract milestone payments. The model is highly scalable — royalty revenue requires virtually no incremental operating expense to grow, and Ligand operates with just 47 employees. Ligand's partners handle all clinical development, regulatory execution, manufacturing, and commercialization.